Neuraxis Q2 2023 revenue down 5% to $646K; net loss widens to $2.24M

Neuraxis, INC

Revenue $646K, -5% YoY from $683K; gross margin improved to 89.5% from 88.4%.
Net loss $2.236M ($1.21/share) vs $1.517M ($0.87/share) in Q2 2022.
IPO completed, net proceeds ~$6.1M; now trading on NYSE American under NRXS.
R&D spend surged to $110K from $14K YoY; G&A rose to $1.51M from $1.13M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neuraxis, INC reported the second quarter ended June 30, 2023 results: revenue $646.0 thousand, net income ($2,235.6) thousand, EPS ($1.21) per common share.

Period: the second quarter ended June 30, 2023
Revenue: $646.0 thousand
Net income: ($2,235.6) thousand
EPS: ($1.21) per common share
Result: reported results

Exact text from the filing

of care for children with abdominal pain related disorders of the gut-brain interactions.” 1 Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $646.0 thousand, representing a decrease of 5% compared to $682.6 thousand in the second quarter of 2022. The decrease was primarily due to ordering patterns of our major customers. Gross profit

View on SEC.gov

Browse all earnings releases →

Neuraxis, INC filing history →

Source: SEC EDGAR

accession 0001493152-23-033281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.